Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Midodrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Midodrine SCHEMBL6033144 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL29367411 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL30917926 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL399213 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41463 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899416 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899425 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL29368755 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41464 | 0.97 | ADRA1A (0.95) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899432 | 0.96 | ADRA1A (0.93) | ADRA1ALMNACYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6566 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-20260000647-A1 | Compositions, Formulations, And Methods Of Treating Neurodegenerative Diseases | APPLIED COGNITION INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4662311-A2 | REVERSIR MOLECULES AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-12458610-B2 | Pharmaceutical composition for treating or preventing diabetic cataract | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-11-04 | — | — | US | claimed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | claimed |
| CN-1269811-A | Polyanhydrides having therapeutically useful degradation properties | RUTGERS THE STATE UNIV (US) | 2000-10-11 | — | — | CN | claimed |
| EP-1032605-A1 | POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS | Rutgers, The State University (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-6078834-A | Device and method for detection and treatment of syncope | PHARMATARGET, INC. (US) | 2000-06-20 | — | — | US | claimed |
| WO-1999012990-A1 | POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS | RUTGERS, THE STATE UNIVERSITY (US) | 1999-03-18 | — | — | WO | claimed |
| US-5466466-A | Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-11-14 | — | — | US | claimed |
| EP-0384266-B1 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LOHMANN THERAPIE SYST LTS (DE) | 1994-07-20 | — | — | EP | claimed |
| US-5215751-A | THERAPEUTIC SYSTEM FOR THE RETARDED AND CONTROLLED TRANSDERMAL OR TRANSMUCOUS ADMINISTRATION OF ACTIVE SUBSTANCES (I) | LTS LOHMANN THERAPIE SYSTEME GMBH & CO. (DE) | 1993-06-01 | — | — | US | claimed |
| EP-0384267-B1 | THERAPEUTIC SYSTEM FOR THE SUSTAINED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL DELIVERY OF ACTIVE AGENTS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1993-05-26 | — | — | EP | claimed |
| EP-0164571-B1 | SUSTAINED-RELEASE FORMS OF ALPHA-(2,5-DIMETHOXY PHENYL)-BETA-GLYCINAMIDOETHANOL AND PROCESS FOR THEIR PREPARATION | CL PHARMA AKTIENGESELLSCHAFT (AT) | 1990-06-27 | — | — | EP | claimed |